摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-cyclohexylquinazolin-4(3H)-one | 26059-80-3

中文名称
——
中文别名
——
英文名称
2-cyclohexylquinazolin-4(3H)-one
英文别名
2-(cyclohexyl)-4-[3H]quinazolinone;2-Cyclohexyl-3,4-dihydro-4-oxo-chinazolin;2-cyclohexyl-3H-quinazolin-4-one
2-cyclohexylquinazolin-4(3H)-one化学式
CAS
26059-80-3
化学式
C14H16N2O
mdl
——
分子量
228.294
InChiKey
MEWDLKFIQDINLZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    389.3±25.0 °C(Predicted)
  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    41.5
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2-cyclohexylquinazolin-4(3H)-oneN,N-二甲基苯胺三氯氧磷 作用下, 以 四氢呋喃 为溶剂, 反应 35.5h, 生成 (2-Cyclohexyl-quinazolin-4-yl)-phenyl-amine
    参考文献:
    名称:
    Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities
    摘要:
    Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.
    DOI:
    10.1021/jm00018a014
  • 作为产物:
    描述:
    环己甲腈羟胺 作用下, 以 neat (no solvent) 为溶剂, 反应 2.5h, 生成 2-cyclohexylquinazolin-4(3H)-one
    参考文献:
    名称:
    调查一些取代的喹唑啉酮与五氟(氯)吡啶的反应性
    摘要:
    通过五氟(氯)吡啶与2-取代的喹唑啉酮的反应,设计并合成了一系列新的由4-杂芳基取代的喹唑啉。五氟(氯)吡啶被喹唑啉酮的芳香亲核取代发生在吡啶环的4位上,是喹唑啉酮的氧位点(以O为中心的亲核试剂)。通过IR,1 H NMR,19 F NMR和13 C NMR光谱以及元素分析确认所有化合物的结构。
    DOI:
    10.1002/jhet.3067
点击查看最新优质反应信息

文献信息

  • Late-Stage C–H Alkylation of Heterocycles and 1,4-Quinones via Oxidative Homolysis of 1,4-Dihydropyridines
    作者:Álvaro Gutiérrez-Bonet、Camille Remeur、Jennifer K. Matsui、Gary A. Molander
    DOI:10.1021/jacs.7b05899
    日期:2017.9.6
    heterocyclic bases and 1,4-quinones. DHPs are readily prepared from aldehydes, and considering that aldehydes normally require harsh reaction conditions to take part in such transformations, with mixtures of alkylated and acylated products often being obtained, this net decarbonylative alkylation approach becomes particularly useful. The present method takes place under mild reaction conditions and requires
    在氧化条件下,1,4-二氢吡啶 (DHP) 发生均裂,仅形成以 Csp3 为中心的自由基,该自由基可以参与杂环碱基和 1,4-醌的 CH 烷基化。DHP很容易由醛制备,并且考虑到醛通常需要苛刻的反应条件来参与这种转化,并且经常获得烷基化和酰化产物的混合物,这种净脱羰烷基化方法变得特别有用。本方法在温和的反应条件下进行,仅需要过硫酸盐作为化学计量氧化剂,使得该方法适合复杂分子的后期CH烷基化。值得注意的是,结构复杂的药剂可以用该方案功能化或制备,例如抗疟药 Atovaquone 和抗疟药 Parvaquone,从而证明其适用性。机理研究揭示了可能通过形成脱芳构中间体的自由基链过程,从而更深入地了解控制这些自由基前体反应性的因素。
  • Organocatalyzed, Visible-Light Photoredox-Mediated, One-Pot Minisci Reaction Using Carboxylic Acids via <i>N</i>-(Acyloxy)phthalimides
    作者:Trevor C. Sherwood、Ning Li、Aliza N. Yazdani、T. G. Murali Dhar
    DOI:10.1021/acs.joc.8b00205
    日期:2018.3.2
    one-pot Minisci reaction has been developed using visible light, an organic photocatalyst, and carboxylic acids as radical precursors via the intermediacy of in situ-generated N-(acyloxy)phthalimides. The conditions employed are mild, demonstrate a high degree of functional group tolerance, and do not require a large excess of the carboxylic acid reactant. As a result, this reaction can be applied to
    已经开发了一种改进的一锅式Minisci反应,该反应使用可见光,有机光催化剂和羧酸作为自由基前体,通过原位生成的N-(酰氧基)邻苯二甲酰亚胺进行中介。所采用的条件是温和的,表现出高度的官能团耐受性,并且不需要大量过量的羧酸反应物。结果,该反应可以应用于具有敏感官能团的药物样支架和分子,从而可以进行后期功能化,这在药物化学中引起了极大的兴趣。
  • Terminal-oxidant-free photocatalytic C–H alkylations of heteroarenes with alkylsilicates as alkyl radical precursors
    作者:Gun Ikarashi、Tatsuya Morofuji、Naokazu Kano
    DOI:10.1039/d0cc03286g
    日期:——

    Alkylsilicates bearing C,O-bidentate ligands could achieve photocatalytic C–H alkylations of heteroarenes under acidic conditions without adding any terminal oxidant.

    烷基硅酸盐携带C,O-双齿配体可以在酸性条件下实现杂环芳烃的光催化C-H烷基化,而无需添加任何末端氧化剂。
  • Molecular Oxygen-Mediated Minisci-Type Radical Alkylation of Heteroarenes with Boronic Acids
    作者:Lizhi Zhang、Zhong-Quan Liu
    DOI:10.1021/acs.orglett.7b03297
    日期:2017.12.15
    The carbon–carbon bond formation via autoxidation of organoboronic acid using 1 atm of O2 is achieved in a simple, clean, and green fashion. The approach allows a technically facile and environmentally benign access to structurally diverse heteroaromatics with medicinally privileged scaffolds. The strategy also displays its practicality and sustainability in the resynthesis of marketed drugs Crestor
    通过使用1个atm的O 2自动氧化有机硼酸来形成碳-碳键,这是一种简单,清洁且绿色的方式。该方法允许在技术上简便且环境友好地使用具有医学特权的支架来访问结构多样的杂芳族化合物。该策略还可以在市售药物Crestor和乙胺嘧啶的再合成中显示其实用性和可持续性。
  • Linear-Organic-Polymer-Supported Iridium Complex as a Recyclable Auto-Tandem Catalyst for the Synthesis of Quinazolinones via Selective Hydration/Acceptorless Dehydrogenative Coupling from <i>o</i>-Aminobenzonitriles
    作者:Shushu Hao、Jiazhi Yang、Peng Liu、Jing Xu、Chenchen Yang、Feng Li
    DOI:10.1021/acs.orglett.1c00475
    日期:2021.4.2
    coordinative immobilization of [Cp*IrCl2]2 on poly(4-vinylpyridine), was proven to be an efficient heterogeneous autotandem catalyst for synthesizing quinazolinones via selective hydration/acceptorless dehydrogenative coupling from o-aminobenzonitriles. Furthermore, the synthesized catalyst was recycled five times without an obvious decrease in the catalytic activity.
    通过将[Cp * IrCl 2 ] 2配位固定在聚(4-乙烯基吡啶)上设计和合成的线性有机聚合物负载的铱络合物Cp * Ir @ P4VP被证明是一种有效的异质串联催化剂通过邻氨基苄腈的选择性水合/无受体脱氢偶联合成喹唑啉酮。此外,将合成的催化剂循环使用五次,而催化活性没有明显降低。
查看更多